A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of ALN-TTR02 in Japanese Healthy Volunteers

Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of ALN-TTR02 in Japanese Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 29 May 2015

At a glance

  • Drugs Patisiran (Primary)
  • Indications Amyloidosis
  • Focus Adverse reactions
  • Sponsors Alnylam Pharmaceuticals
  • Most Recent Events

    • 22 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Aug 2014 According to an Alnylam Pharmaceuticals media release, this study is intended to support the expansion of the APOLLO trial to include sites in Japan.
    • 22 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top